divislab glp-1 novo nordisk relation A $60 billion industry just found its next growth lever. 💊 With the expiry of a key patent on March 20, 2026, Indian pharma majors are launching generic weight-loss and diabetes drugs Deep Dive: Revisiting Novo Nordisk

Interestingly, a comparison of acute metabolic responses with the chronic profiles at the end of the treatment period strongly suggests that while the different GLP1-based agonists may share primary mechanisms of action, the durability and efficiency of their long-term metabolic responses differ, with clear superiority for the GLP1/E compound

Beneficios de la L-Carnitina Cmo funciona la L-Carnitina

A Stronger Emphasis on Shared Decision-Making The 2026 guidelines reinforce that diabetes care starts with the person, not the number

"There were people out there that many folks looked up to who were in larger bodies, and there has really been some grief around losing that representation," she says